FORM traded down -12.15% to $121.38 as of 1:48 p.m. ET on Tuesday, versus a prior close of $138.16; the decline extended a gap-down open during regular trading. The primary catalyst was disclosure that CEO Mike Slessor sold 16,002 shares (~$2.10 million) on Aug. 14 under a pre-arranged Rule 10b5-1 plan, cutting his stake by about 3.2%.

BIDU is down -13.28% at $90.29 as of 1:48 p.m. ET, versus Monday's close of $104.12; the decline deepened during the regular session after premarket losses. Primary catalyst: Q2 earnings missed estimates—revenue fell -4% year over year to RMB31.33B vs RMB31.95B consensus, and adjusted EPS of RMB7.22 missed RMB9.84.

CBRS is down -14.42% during regular trading, sliding to about $215.65 after Monday's close at $251.98. The decline reverses Monday's +15.07% surge tied to reports linking Cerebras to OpenAI's GPT-5.6 Sol Ultrafast inference tier.

MXL is trading down -14.28% at $72.66 during the regular session as of roughly 1:45 PM ET, versus a prior close of $84.76. The move is part of a broad optical-communications and semiconductor selloff, with the sector down about -6.6% and peers also falling sharply.

AEHR is down -15.17% in regular trading Tuesday, falling to $123.52 from Monday's close of $145.61 as of early afternoon. The drop is a sharp profit-taking reversal after a vertical run: shares had more than doubled from late-July lows and hit a record $147.40 on Aug 14.

AXTI traded down -14.98% at $81.59 during Tuesday's regular session as of 1:43 p.m. ET, versus Monday's $95.97 close. The decline began with a -6.7% premarket dip and accelerated after the open.

VNET Group shares are down -17.17% to about $6.56 during regular trading Tuesday after gapping lower in premarket on Q2 results. Q2 revenue rose +14.2% Y/Y to RMB2.78B ($409M) and adjusted EBITDA grew +25.4%, but the GAAP net loss widened to RMB135.6M.

IPST is up +138.43% during Tuesday's regular session, last trading at $17.62 as of 11:07 a.m. ET, versus Monday's close of $7.39. The move follows a roughly -3.4% premarket dip and extends Monday's +235.89% low-float surge, with no conventional same-day press release driving the spike.

Profusa shares are up +233.11% to $15.09 in Tuesday regular trading as of 10:29 a.m. ET, versus Monday's close of $4.53. The move extends premarket and overnight gains after the company's 1-for-4 reverse stock split became effective, reducing shares outstanding from about 2.42 million to roughly 605,726.

WEAV shares climbed +31.83% to $7.29 during regular trading, versus a prior-session close of $5.53. The intraday surge followed Weave's announcement of a definitive agreement to be acquired by Francisco Partners.

AMLX is up +33.08% to $28.52 in regular trading as of 9:40 a.m. ET, versus a $21.43 prior-session close, after surging in Monday after-hours and premarket. Primary catalyst: Amylyx reported positive Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia, meeting the primary endpoint with a statistically significant 55% reduction in Level 2/3 hypoglycemic events versus placebo.

KLAR traded at $15.73 in early regular trading, down -19.37% from Monday's $19.51 close; the slide began premarket after Q2 results. Q2 beat estimates—revenue rose +27% to $1.04B and adjusted EPS of +$0.01 exceeded a -$0.05 loss consensus—but guidance drove the selloff.

Fabrinet (FN) is trading down -14.28% at $513.11 during the regular session, versus Monday's close of $598.58. The move follows fiscal Q4 results released after Monday's close; shares fell ~7% after-hours and extended losses in premarket trading.

Selected price target: $43, matching the highest published Wall Street analyst target for CNK in recent months. Current position: Cinemark shares recently traded near $37.50, just below the 52-week high of $38.98, leaving roughly 15% upside to the $43 target.

NIQ Global Intelligence shares rose 56.8% in the 30-day period ended August 17, 2026, climbing from $11.00 to $17.25. The move accelerated sharply after second-quarter 2026 results, when adjusted EPS of $0.27 beat a consensus estimate near $0.20.

BETA shares advanced about 44% over the last 30 days, from a $17.76 close on July 17, 2026, to $25.60 on Aug. 17, 2026. Over the trailing quarter, the stock has climbed roughly 66% from a $15.41 close on May 15, 2026.

Ondas Inc. ( ONDS ) closed near $9.00 in mid-August 2026, so a move to the $20 stock price target would require roughly 120% upside. The strongest bull case rests on record second-quarter 2026 revenue, raised full-year guidance, a growing order backlog, and U.S. policy tailwinds for domestic drone and defense technology.

Oil and natural gas price fluctuations remain the primary macroeconomic sensitivity, directly influencing exploration and production (E&P) capital expenditure budgets and rig demand. Helmerich & Payne’s FlexRig technology and efficiency-focused fleet position the company to benefit from industry shifts toward higher-specification, lower-emission drilling solutions.

Paymentus Holdings shares rose about 36.5% over the 30 days through the August 17, 2026 close, climbing from $29.78 to $40.66. The primary catalyst was second-quarter 2026 results reported August 3, 2026: record revenue of $360.7 million, up 28.8% year over year, with adjusted EBITDA up 54%.

MMED shares climbed roughly 15.4% over the last 30 days, from a closing price of $16.93 on July 17, 2026, to $19.53 at the latest available close. The advance was supported by expanded U.S. Medicare access to the MiniMed Flex system, the start of commercial U.S. shipments with Abbott's Instinct sensor, and favorable analyst actions.